Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial Fibrillation

Curr Med Sci. 2025 Apr;45(2):157-168. doi: 10.1007/s11596-025-00021-7. Epub 2025 Mar 4.

Abstract

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with a multifactorial pathophysiology involving electrical, structural, and autonomic remodeling of the atria. AF is closely associated with elevated interleukin-6 (IL-6) levels, which contribute to atrial remodeling and the progression of AF. This review summarizes the mechanisms by which IL-6 promotes AF through inflammatory pathways, atrial fibrosis, electrical remodeling, and calcium mishandling. Experimental models have demonstrated that IL-6 neutralization reduces the incidence of AF, highlighting its potential as a therapeutic target. Future studies should focus on IL-6 blockade strategies to manage AF, aiming to improve patient outcomes.

Keywords: Atrial fibrillation; Atrial remodeling; Inflammation; Interleukin-6; Therapeutic targets.

Publication types

  • Review

MeSH terms

  • Animals
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / genetics
  • Atrial Fibrillation* / metabolism
  • Atrial Fibrillation* / pathology
  • Atrial Fibrillation* / physiopathology
  • Atrial Remodeling
  • Fibrosis
  • Heart Atria / metabolism
  • Heart Atria / pathology
  • Heart Atria / physiopathology
  • Humans
  • Inflammation
  • Interleukin-6 Inhibitors*
  • Interleukin-6* / genetics
  • Interleukin-6* / metabolism

Substances

  • Interleukin-6
  • Interleukin-6 Inhibitors
  • IL6 protein, human